UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 43

Sortiert nach

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

Clinical cancer research, 2017-07, Vol.23 (14), p.3638-3648

2017

Volltextzugriff (PDF)

The status of hematopoietic stem cell transplantation in lysosomal storage disease

Pediatric neurology, 2003-11, Vol.29 (5), p.391-403

2003

Volltextzugriff (PDF)

Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study

Gynecologic oncology, 2020-03, Vol.156 (3), p.523-529

2020

Volltextzugriff (PDF)

ELU-FRα-1: A study to evaluate ELU001 in patients with solid tumors that overexpress folate receptor alpha (FRα)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3158-TPS3158

2022

Volltextzugriff (PDF)

Phase 1 trial of a novel C’Dot drug conjugate (CDC), ELU001, in patients with solid tumors known to overexpress folate receptor alpha (FRα)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS3159-TPS3159

2023

Volltextzugriff (PDF)

Abstract 305: ELU001, a targeted C'Dot drug conjugate (CDC) for the treatment of folate receptor alpha (FRα) overexpressing cancers

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.305-305

2021

Volltextzugriff (PDF)

A phase I study of the bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS3091-TPS3091

2017

Volltextzugriff (PDF)

Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS3132-TPS3132

2018

Volltextzugriff (PDF)

Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.TPS81-TPS81

2018

Volltextzugriff (PDF)

Preliminary biomarker and pharmacodynamic data from a phase I study of single-agent bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.69-69

2018

Volltextzugriff (PDF)

P-287 Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): a randomized, open-label phase 2 study

Annals of oncology, 2016-06, Vol.27, p.ii84-ii84

2016

Volltextzugriff (PDF)

P-287Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): a randomized, open-label phase 2 study

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii84-ii84

2016

Volltextzugriff (PDF)

A randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC)

Journal of clinical oncology, 2016-02, Vol.34 (4_suppl), p.TPS482-TPS482

2016

Volltextzugriff (PDF)

Abstract CT255: ELU-FRα-1: a study to evaluate ELU001 in patients with solid tumors that overexpress folate receptor alpha (FRα)

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT255-CT255

2023

Volltextzugriff (PDF)

Nanoliposomal irinotecan in metastatic pancreatic cancer – Authors' reply

The Lancet (British edition), 2016-05, Vol.387 (10032), p.1997-1997

2016

Volltextzugriff (PDF)

Abstract 837: Preclinical development of ELU001: A folate receptor alpha (FRα)-targeted C’Dot drug conjugate (CDC) for the treatment of brain metastases

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.837-837

2023

Volltextzugriff (PDF)

Vasculopathy of small muscular arteries in pediatric patients after bone marrow transplantation

Human pathology, 1999-07, Vol.30 (7), p.734-740

1999

Volltextzugriff (PDF)

Abstract P5-01-06: Characterization of metastatic breast cancer lesions with ferumoxytol MRI and treatment response to MM-398, nanoliposomal irinotecan (nal-IRI)

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P5-P5-01-06

2015

Volltextzugriff (PDF)

Abstract 1077: Stability and safety evaluation of ELU001, a targeted C’Dot drug conjugate for the potential treatment of folate receptor alpha-overexpressing cancers

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.1077-1077

2022

Volltextzugriff (PDF)

A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors

Pediatric blood & cancer, 2012-11, Vol.59 (5), p.865-869

2012

Volltextzugriff (PDF)

Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration Regimens

Clinical breast cancer, 2014-12, Vol.14 (6), p.396-404

2014

Volltextzugriff (PDF)

Abstract CT224: Pilot study in patients with advanced solid tumors to evaluate feasibility of ferumoxytol (FMX) as tumor imaging agent prior to MM-398, a nanoliposomal irinotecan (nal-IRI)

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.CT224-CT224

2014

Volltextzugriff (PDF)

Abstract 2065: Magnetic resonance imaging with an iron oxide nanoparticle demonstrates the preclinical feasibility of predicting intratumoral uptake and activity of MM-398, a nanoliposomal irinotecan (nal-IRI)

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2065-2065

2014

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(43)

Sprache

Englisch
(43)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(19)
Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Male
(11)
Female
(10)
Biological And Medical Sciences
(9)
Adolescent
(8)
Medical Sciences
(8)
Oncology
(8)
Child
(7)
Adult
(6)
Bone Marrow Transplantation
(6)
Pediatrics
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Bone Marrow Cells
(4)
Hematology
(4)
Middle Aged
(4)
Cell Division - Drug Effects
(3)
Cells, Cultured
(3)
Child, Preschool
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

The status of hematopoietic stem cell transplantation in lysosomal storage disease

Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study

ELU-FRα-1: A study to evaluate ELU001 in patients with solid tumors that overexpress folate receptor alpha (FRα)

Phase 1 trial of a novel C’Dot drug conjugate (CDC), ELU001, in patients with solid tumors known to overexpress folate receptor alpha (FRα)

Abstract 305: ELU001, a targeted C'Dot drug conjugate (CDC) for the treatment of folate receptor alpha (FRα) overexpressing cancers

A phase I study of the bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers

Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma

Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma

Preliminary biomarker and pharmacodynamic data from a phase I study of single-agent bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers

P-287 Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): a randomized, open-label phase 2 study

P-287Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): a randomized, open-label phase 2 study

A randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC)

Abstract CT255: ELU-FRα-1: a study to evaluate ELU001 in patients with solid tumors that overexpress folate receptor alpha (FRα)

Nanoliposomal irinotecan in metastatic pancreatic cancer – Authors' reply

Abstract 837: Preclinical development of ELU001: A folate receptor alpha (FRα)-targeted C’Dot drug conjugate (CDC) for the treatment of brain metastases

Vasculopathy of small muscular arteries in pediatric patients after bone marrow transplantation

Abstract P5-01-06: Characterization of metastatic breast cancer lesions with ferumoxytol MRI and treatment response to MM-398, nanoliposomal irinotecan (nal-IRI)

Abstract 1077: Stability and safety evaluation of ELU001, a targeted C’Dot drug conjugate for the potential treatment of folate receptor alpha-overexpressing cancers

A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors

Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration Regimens

Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy

Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

Abstract CT224: Pilot study in patients with advanced solid tumors to evaluate feasibility of ferumoxytol (FMX) as tumor imaging agent prior to MM-398, a nanoliposomal irinotecan (nal-IRI)

Abstract 2065: Magnetic resonance imaging with an iron oxide nanoparticle demonstrates the preclinical feasibility of predicting intratumoral uptake and activity of MM-398, a nanoliposomal irinotecan (nal-IRI)

Suchergebnisse filtern